SCHEMBL352848

SCHEMBL352848

Cc1cscc1Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38660494 0.94
SCHEMBL319580 0.75
SCHEMBL129408 0.75
SCHEMBL13879062 0.69 CYP2A6 (0.62)
SCHEMBL38660079 0.69
SCHEMBL14666897 0.64 MAPT (0.32)
SCHEMBL21720519 0.63 SMN1; SMN2 (0.31)
SCHEMBL19881200 0.63
SCHEMBL4026792 0.63
SCHEMBL9631841 0.63

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383856-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-11-21 US claimed
CN-118591529-A Deuterated ROCK inhibitors, pharmaceutical compositions and therapeutic applications 维眸生物科技(浙江)有限公司 2024-09-03 CN claimed
US-20150093435-A1 TREATMENT OF LENGTH DEPENDENT NEUROPATHY ARC1, INC. 2015-04-02 US claimed
US-8026266-B2 Treatment of length dependent neuropathy ARCION THERAPEUTICS, INC. (US) 2011-09-27 US claimed
US-20110142920-A1 TREATMENT OF LENGTH DEPENDENT NEUROPATHY ARCION THERAPEUTICS, INC. 2011-06-16 US claimed
US-RE41998-E1 Compositions and methods of treatment of sympathetically maintained pain Arclon Therapeutics, Inc. (US) 2010-12-14 US claimed
EP-1962836-A2 TREATMENT OF LENGTH DEPENDENT NEUROPATHY Arcion Therapeutics, Inc. (US) 2008-09-03 EP claimed
CN-101237867-A Novel 4-amino-thieno[3,2-C]pyridine-7-carboxylic acid amides HOFFMANN LA ROCHE (CH) 2008-08-06 CN claimed
US-20070142385-A1 TREATMENT OF LENGTH DEPENDENT NEUROPATHY ARC1, INC. 2007-06-21 US claimed
WO-2007056460-A2 TREATMENT OF LENGTH DEPENDENT NEUROPATHY ARCION THERAPEUTICS, INC. (US) 2007-05-18 WO claimed
US-4526962-A Cephalosporin derivatives RHONE-POULENC SANTE (FR) 1985-07-02 US claimed
CN-117177975-B Pyrimido [5,4, D ] pyrimidine compounds, compositions comprising the same and uses thereof 蒙特利尔大学 2026-05-19 CN disclosed
US-12479842-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease UNIVERSITE DE MONTREAL (CA) 2025-11-25 US disclosed
US-20250270207-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE UNIVERSITE DE MONTREAL (CA) 2025-08-28 US disclosed
US-12139488-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease Université de Montréal (CA) 2024-11-12 US disclosed
US-6559186-B1 Pain is treated topically by administering to the site where sympathetically maintained pain is present an alpha -1-adrenergic antagonist, alpha -2- adrenergic agonist, or other drug that depletes or blocks synthesis of sympathetic ARC 1, INC. 2003-05-06 US disclosed
EP-0573581-A4 COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN ARC 1 INC (US) 1994-06-29 EP disclosed
EP-0573581-A1 COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN ARC 1, Inc. (US) 1993-12-15 EP disclosed
WO-1992014453-A1 COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN ARC 1, INC. (US) 1992-09-03 WO disclosed
US-4526962-A Cephalosporin derivatives RHONE-POULENC SANTE (FR) 1985-07-02 US disclosed